schizophrenia. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although
Conditions
Interventions
Intervention 1: Sertraline, tab 50 mg, oral, once a day, for 6 weeks. Intervention 2: Placebo, tab 50 mg, oral, once a day, for 6 weeeks.
Treatment - Drugs
Placebo
Sertraline, tab 50 mg, oral, once a day, for 6 weeks
Placebo, tab 50 mg, oral, once a day, for 6 weeeks
Sponsors
Vice Chancellor for Research and Technology Development-Ahwaz Jondishapur University of Medical Sci
Eligibility
Sex/Gender
All
Age
21 Years to 63 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for this study are as follows: schizophrenia - a negative score more than 15 in PANSS; no liver disease; not treated with ECT in the past six months; during illness for over one year; aged between 21 to 63 years old. The Exclusion criteria are: depression; mental retardation; schizoaffective disorder; bipolar disorder; a neurological disorder such as epilepsy, Parkinson's disease; a risky physical illness such as cardiac ischemia or heart failure; use of antidepressants or lithium for whatever reason; Leisure drug; drug abuse within one recent month (except nicotine and caffeine); extrapyramidal side effects; deafness or dumbness active suicidal or homicidal thoughts; pregnant or lactating women; at least 3 months have passed since the last time the use of long-acting antipsychotics; drugs with a history of hypersensitivity or serious interest in the study; the patient withdrew from the study and side effects.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Emotional withdrawal. Timepoint: Before intervention,1 week after intervention, 3 weeks after intervention, 6 weeks after intervention. Method of measurement: PANSS(Positive and Negative Symptom Scale).;Social withdrawal. Timepoint: Before intervention, 1 week after intervention, 3 weeks after intervention, 6 weeks after intervention. Method of measurement: PANSS(Positive and Negative Symptom Scale).;Blunted affect. Timepoint: Before intervention,1 week after intervention, 3 weeks after intervention, 6 weeks after intervention. Method of measurement: PANSS(Positive and Negative Symptom Scale).;Other negative symptoms. Timepoint: Before intervevtion, 1 week after intervention, 3 weeks after intervention, 6 weeks after intervention. Method of measurement: PANSS(Positive and Negative Symptom Scale). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: One week after intervention,3 weeks after intervention,6 weeks after intervention. Method of measurement: Interview with patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Seyed Moammad Seyed Ghafari Dezfuli
Ahwaz Jondishapur University of Medical Sciences
Outcome results
None listed